Management buyout at Quotient Bioresearch
Existing private equity shareholder provides finance
Quotient Bioresearch has been bought by its management with finance from private equity firm TA Associates, which already had a stake in the business. Terms of the deal were not disclosed.
Quotient is a UK-based provider of outsourced development services, employing more than 500 people and serving the pharmaceutical and life science industries. It mainly targets the early stages of drug development and its services are based upon its chemistry, metabolism, bioanalytical and clinical capabilities.
The company is growing at a rate of more than 20% a year.
The management buyout team was led by ceo Roger Burdett and cfo Gordon Cameron. TA Associates is a private equity firm with more than US$16bn of capital.
